Malignant Melanoma Therapy by Chemotherapy and Autoimmunity Induced by Cytokine

Shi, Jin; Zhang, Qingyuan; Kang, Xinmei; Wang, JingXuan; Sun, Wenzhou

doi:10.1089/cbr.2008.0552

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical efficacy in studies varied widely, with response rates ranging from no response to >40% [53-58]. It is worth noting that several of the studies reporting high overall response rates also reported significant increases in T-cell, DC, macrophage, or natural killer–cell populations following treatment [53,55,58]. One study evaluating a chemotherapy regimen of dacarbazine, interferon-α2b, interleukin-2, and tamoxifen with three doses of GM-CSF reported a dose–response effect with increasing exposure to GM-CSF via administration over a greater number of days ( P = 0.016) [59].…”

Section: Reviewmentioning

confidence: 99%

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Kaufman¹,

Ruby²,

Hughes³

et al. 2014

j. immunotherapy cancer

189

131

View full text Add to dashboard Cite

In 2012, it was estimated that 9180 people in the United States would die from melanoma and that more than 76,000 new cases would be diagnosed. Surgical resection is effective for early-stage melanoma, but outcomes are poor for patients with advanced disease. Expression of tumor-associated antigens by melanoma cells makes the disease a promising candidate for immunotherapy. The hematopoietic cytokine granulocyte–macrophage colony-stimulating factor (GM-CSF) has a variety of effects on the immune system including activation of T cells and maturation of dendritic cells, as well as an ability to promote humoral and cell-mediated responses. Given its immunobiology, there has been interest in strategies incorporating GM-CSF in the treatment of melanoma. Preclinical studies with GM-CSF have suggested that it has antitumor activity against melanoma and can enhance the activity of anti-melanoma vaccines. Numerous clinical studies have evaluated recombinant GM-CSF as a monotherapy, as adjuvant with or without cancer vaccines, or in combination with chemotherapy. Although there have been suggestions of clinical benefit in some studies, results have been inconsistent. More recently, novel approaches incorporating GM-CSF in the treatment of melanoma have been evaluated. These have included oncolytic immunotherapy with the GM-CSF–expressing engineered herpes simplex virus talimogene laherparepvec and administration of GM-CSF in combination with ipilimumab, both of which have improved patient outcomes in phase 3 studies. This review describes the diverse body of preclinical and clinical evidence regarding use of GM-CSF in the treatment of melanoma.

show abstract

Section: Reviewmentioning

confidence: 99%

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Kaufman¹,

Ruby²,

Hughes³

et al. 2014

j. immunotherapy cancer

189

131

View full text Add to dashboard Cite

show abstract

“…Autoimmunity is generally recognized as a possible severe side effect of melanoma therapy, upon interferon- [ 22 ] or ipilimumab-treatment [ 23 ]. On the other hand, unchaining the immune system is the main goal of current immunotherapy protocols as well as previous approaches combining dacarbazine with IL-2 and GM-CSF [ 24 ]. Data published in 2018 indicate a high prevalence rate of pre-existing autoimmune comorbidities in melanoma patients as compared to the general population (28.3% and 19.8% in metastatic and not-metastatic melanoma, respectively, as compared to 9.2% in the general population) [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Expression of Autoimmunity-Related Genes in Melanoma

Scatozza

Facchiano

2022

Cancers

View full text Add to dashboard Cite

(1) Background. Immune response dysregulation plays a key role in melanoma, as suggested by the substantial prognosis improvement observed under immune-modulation therapy. Similarly, the role of autoimmunity is under large investigation in melanoma and other cancers. (2) Methods. Expression of 98 autoimmunity-related genes was investigated in 1948 individuals (1024 melanoma and 924 healthy controls). Data were derived from four independent databases, namely, GEO in the selection phase, and Ist Online, GEPIA2 and GENT2, in three sequential validation-steps. ROC analyses were performed to measure the ability to discriminate melanoma from controls. Principal Component Analysis (PCA) was used to combine expression data; survival analysis was carried out on the GEPIA2 platform. (3) Results. Expression levels of NOD2, BAX, IL-18 and ADRB2 were found to be significantly different in melanoma vs. controls and discriminate melanoma from controls in an extremely effective way, either as single molecules (AUC > 0.93 in all cases) or as a profile, according to the PCA analysis. Patients showing high-expression of NOD2 and of IL-18 also show a significant survival improvement as compared to low-expression patients. (4) Conclusions. Four genes strongly related to autoimmunity show a significant altered expression in melanoma samples, highlighting the role they may play in melanoma.

show abstract

Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice

Huang

Zhou

et al. 2010

Cytokine

View full text Add to dashboard Cite

Malignant Melanoma Therapy by Chemotherapy and Autoimmunity Induced by Cytokine

Abstract: The combination of DTIC with GM-CSF and IL-2 is feasible and possibly efficacious for clinical use.

Cited by 3 publications

References 13 publications

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Expression of Autoimmunity-Related Genes in Melanoma

Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice

Contact Info

Product

Resources

About